New Baxalta drug emerges in Pfizer-monopolizing hemophilia B market

In the domestic hemophilia B(congenital factor ix deficiency) market which had been monopolized by Pfizer with Benefix, a rival emerged.

Recently, the Ministry of Health and Welfare(MOHW) administratively notified the ‘Amendment Announcement to Details on Application Standards and Methods of Insurance Benefits’ which includes the contents to apply a hemophilia B treatment ‘Rixubis(manufacture...